European Society for Medical Oncology (ESMO)

The European Society for Medical Oncology (ESMO) is the leading professional organisation for medical oncology. With more than 25,000 members representing oncology professionals from over 150 countries worldwide, ESMO was founded in 1975.
Results from the KEYNOTE-100 study show that expression of PD-L1 and inflamed T-cell–associated genes are associated with clinical response in advanced, recurrent ovarian cancer. Read More ›

This combination of antiangiogenic and immune checkpoint blockade has clinical activity in women with recurrent ovarian cancer. Read More ›

Results from the phase 3 SOLO1 trial demonstrate a substantial, unprecedented improvement in progression-free survival for olaparib versus placebo. Read More ›

Based on the tolerable safety profile established in phase 1b of the ORION-01 trial, the recommended dose for expansion/recommended phase 2 dose of the oregovomab/nivolumab combination immunotherapy has been established. Read More ›

In a prospective trial, the VEGFR-2 small-molecule inhibitor apatinib has shown promising efficacy and safety signals. Read More ›

Fatigue and neuropathy were found to be common in patients treated with olaparib, and should be identified and managed early. Read More ›

A groundbreaking report presented today at ESMO conveyed data from an interim analysis of a phase 2b trial demonstrating that the combination of NPS + trastuzumab is safe and may provide clinically meaningful benefit to women with HER2 low-expressing breast cancer, with a particularly marked benefit in the subgroup with triple-negative breast cancer. Read More ›


The French SIGNAL and PHARE projects have collected data on more than 9800 patients with breast cancer since 2006. In evaluating the outcomes of sequential and concomitant administration of trastuzumab within this cohort, this study provides insight into the ideal administration protocol for patients with human epidermal growth factor receptor 2–positive (HER2+) breast cancer. Read More ›

The 21-gene Recurrence Score® is the result of a commercial genomic test that evaluates the likelihood that breast cancer will recur, and the likely benefit from chemotherapy and/or radiation therapy. This study evaluates disparities in hormone receptor–positive (HR+) breast cancer outcome by age and 21-gene Recurrence Score®. Read More ›

Page 5 of 9